Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-1451 SAD in Healthy Volunteers
NCT07570147Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-1451 (8 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at Day 211, Maximum Observed Plasma Concentration at Day 211 and 5 more. Started May 2026; status: recruiting.
02
Drugs
ABBV-1451
Beyond the preview
Go deeper on NCT07570147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570147.